Stay updated with breaking news from Palbociclib Ibrance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.
$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,...
Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.
Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.
Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019. - Click here if this is your press release! - eTurboNews | Trends | Travel News